Single-cell maps reveal how enhancers regulate their target genes

Genomic dark matter has long been the paradox at the heart of human genetics. The vast majority of disease-associated DNA variants identified by genome-wide association studies do not sit inside protein-coding genes at all; they cluster in enhancers, the regulatory sequences that act like distant control switches, dialing gene activity up or down from tens or hundreds of thousands of base pairs away. The central obstacle to interpreting these variants has been a simple but stubborn problem: knowing which enhancer controls which gene, in which cell type, under which conditions. A new study published in Nature Genetics presents a computational framework for mapping enhancer–gene regulatory interactions directly from single-cell data, offering researchers a way to connect the noncoding variants unearthed by population genetics to the specific genes and cellular contexts they influence.

The work, led by Mitali U. Sheth, Wen-Lyong Qiu, Xiang Ru Ma and colleagues, addresses a gap that has widened as single-cell genomics has exploded in scale. Technologies such as single-cell RNA sequencing can now measure gene expression in hundreds of thousands of individual cells simultaneously, and single-cell ATAC-seq can profile chromatin accessibility, revealing which regulatory regions are open and potentially active in each cell. But these measurements, taken separately, do not by themselves reveal regulatory wiring. An enhancer may be accessible in a neuron, yet without evidence linking its activity to a target gene’s expression, its functional role remains speculative. Traditional approaches to establishing enhancer–gene links, such as CRISPR-based enhancer deletion or perturbation screens, are powerful but labor-intensive and difficult to scale across the enormous diversity of cell types in complex tissues.

The framework developed by the team leverages a key statistical insight: regulatory interactions leave fingerprints in the natural variation of gene expression and chromatin state across cells. If an enhancer genuinely controls a gene, then across the thousands of cells captured in a single-cell dataset, variation in that enhancer’s activity should be correlated with variation in the target gene’s expression, with effects that appear at the expected genomic distance and that are shaped by transcription factor binding motifs embedded in the enhancer sequence. By aggregating these weak signals across large cell populations and modeling them jointly, the method can distinguish true regulatory links from the many spurious correlations that arise from shared cellular states, cell cycle effects, or batch artifacts — confounders that have historically plagued correlation-based enhancer–gene inference.

A critical component of the approach is its handling of confounding at the level of cell identity. Because all genes in a given cell type tend to rise and fall together, naive correlation analysis assigns enhancers promiscuously to nearby genes, inflating the apparent regulatory network. The new method explicitly models and removes this shared component of variation, isolating the residual, enhancer-specific signal that reflects direct regulation. It also incorporates prior biological knowledge, including enhancer–promoter distance constraints, chromatin contact frequency data from technologies such as Hi-C and promoter capture assays, and sequence features that indicate which transcription factors bind a given enhancer. The result is a ranked set of candidate enhancer–gene pairs for each cell type, each accompanied by a quantitative confidence score that researchers can use to prioritize downstream experimental validation.

To benchmark the framework, the authors compared its predictions against gold-standard perturbation data — instances in which individual enhancers had been experimentally deleted or repressed and the resulting change in target gene expression measured directly. Across the validation sets, the computational predictions recovered a substantial fraction of experimentally confirmed enhancer–gene pairs while maintaining specificity, meaning they did not drown the true positives in a sea of false links. Notably, the method correctly identified many cases in which the nearest gene is not the actual target, a phenomenon that single-cell perturbation screens have increasingly shown to be common. Enhancers frequently skip over adjacent genes to contact promoters further away, and distance-based or nearest-gene assumptions systematically miss these long-range relationships.

One of the most striking demonstrations of the framework’s power comes from its application to disease genetics. When the researchers overlaid genome-wide association study summary statistics for a range of traits and diseases onto their enhancer–gene maps, they were able to trace risk variants to plausible target genes in a cell-type-specific manner. This step is where the method’s value becomes tangible for translational research. A noncoding variant associated with, say, an autoimmune disorder may lie within an enhancer active only in a specific subset of immune cells; by linking that enhancer to its gene targets computationally, researchers gain immediate hypotheses about the molecular mechanism of disease risk and the cellular context in which it operates. The maps effectively convert a list of statistically associated genomic coordinates into a functional annotation, complete with directionality and tissue relevance.

The study also illustrates how the same regulatory architecture can produce different outcomes in different cell types. The authors found that a substantial proportion of enhancers exhibit cell-type-specific target preferences: a given regulatory element may drive expression of one gene in a cortical neuron and an entirely different gene in an astrocyte, even when both cell types share the same underlying genome. This context dependence has major implications for interpreting both normal development and disease. It means that a single variant in a pleiotropic enhancer can contribute to multiple phenotypes through distinct target genes depending on where it is active, and it underscores why bulk-tissue studies, which average signals across mixed cell populations, often fail to resolve the relevant biology.

Technically, the framework operates on paired or unpaired single-cell multi-ome data, in which gene expression and chromatin accessibility are profiled either in the same individual cells or in parallel samples from the same biological condition. The method constructs a graph-based representation of cell-to-cell similarity, smooths sparse single-cell measurements over this graph to recover signal lost to dropout and shallow sequencing depth, and then evaluates enhancer–gene relationships using a regularized regression model that jointly considers all candidate enhancers within a defined genomic window around each gene. Regularization is essential: with tens of thousands of candidate enhancers competing to explain each gene’s expression, the model must penalize complexity to avoid overfitting noise. The learned weights, combined with the motif and chromatin contact priors, yield the final interaction scores. The authors have made the pipeline available to the community, and its computational design allows it to scale to the atlas-sized datasets — millions of cells spanning dozens of tissues — that are now being generated by consortia worldwide.

The implications extend well beyond human genetics. Enhancer–gene maps of this kind provide a substrate for studying gene regulatory network evolution, allowing comparative analyses of how regulatory wiring differs between species or between healthy and diseased states. In cancer genomics, where structural variants frequently rewire enhancer–promoter contacts to activate oncogenes, cell-type-resolved regulatory maps could help identify which tumors depend on which enhancer hijacking events. In developmental biology, the framework offers a way to trace how transcriptional programs are controlled as cells progress through differentiation, capturing transient regulatory relationships that exist only in rare intermediate cell states — populations too small and too fleeting to study with bulk methods.

Limitations remain, and the authors are careful to acknowledge them. Correlation-based inference, however sophisticated, cannot fully substitute for direct perturbation; some predicted interactions will prove false when tested experimentally, and some true interactions may be missed if the relevant enhancing activity is rare or condition-specific. Single-cell datasets also under-sample rare cell types, meaning that regulatory maps for those populations will be less complete. Moreover, chromatin accessibility is an imperfect proxy for enhancer activity: an open region is not necessarily an active enhancer, and methods that read out actual enhancer transcription, such as single-cell eRNA detection, could add further resolution in the future. The integration of the computational maps with systematic CRISPR perturbation screens — using the predictions to guide which enhancers to test — represents a promising hybrid strategy that combines scale with causal certainty.

What the study ultimately delivers is a change in the default assumption researchers can make when confronted with a noncoding variant. Where the fallback was once the nearest gene, it can now be a cell-type-specific, confidence-scored list of candidate targets derived from the collective behavior of thousands of single cells. As single-cell atlases continue to grow and as perturbation technologies mature, frameworks like this one are positioned to become standard infrastructure for interpreting the regulatory genome — the layer of DNA that, despite encoding no proteins, orchestrates when, where, and how much every gene is expressed. In bridging the gap between variant catalogs and mechanism, the work brings the field measurably closer to the long-promised era of actionable noncoding genetics.